The frantic global effort to test people for COVID-19 pushed Roche’s diagnostics division to record revenue, helping the Swiss drugmaker offset declining drug sales and keeping it on track to meet full-year 2020 targets. Sales of diagnostics including tests for the new coronavirus, of which Roche offers several to both detect active and past infections, rose 2% through September to 9.7 billion Swiss francs ($10.6 billion), even when taking into account the Swiss franc’s strength that eroded revenue in the United States and Europe. Roche shares were seen falling 1.9%, according to premarket indicators from Bank Julius Baer. …read more
Source:: Yahoo Finance
